Chemokines in Gestational Diabetes Mellitus

Area of Science:

• Immunology
• Endocrinology
• Reproductive Medicine

Background:

• Gestational diabetes mellitus (GDM) is a growing concern in pregnancy.
• Previous studies on chemokines in GDM have shown conflicting results.
• Chemokines are crucial in immune cell trafficking and inflammation, potentially playing a role in GDM pathogenesis.

Purpose of the Study:

• To systematically analyze and compare chemokine concentrations in patients with GDM versus healthy controls.
• To clarify the association between specific chemokines and the development of GDM.

Main Methods:

• A comprehensive meta-analysis was conducted following PRISMA guidelines.
• Searched major databases (PubMed, Embase, Web of Science, Cochrane Library) for relevant studies up to August 2021.
• Analyzed data from 17 studies involving 5,158 participants using a random-effects model to determine standardized mean differences in chemokine concentrations.

Main Results:

• Seventeen studies with 5,158 participants (1,934 GDM, 3,224 controls) were included.
• Significant increases in CCL2, CXCL1, CXCL8, CXCL9, and CXCL12 were observed in GDM patients.
• Significant decreases in CCL4, CCL11, and CXCL10 were noted in GDM patients.
• Subgroup analyses indicated chemokines may serve as biomarkers influenced by sample type, assay methods, ethnicity, and BMI.

Conclusions:

• GDM is associated with distinct alterations in multiple chemokines (CCL2, CCL4, CCL11, CXCL1, CXCL8, CXCL9, CXCL10, CXCL12).
• These chemokines warrant consideration as potential biomarkers and therapeutic targets in GDM.
• Further research into the underlying mechanisms is essential for developing personalized GDM management strategies.